Promote secretion of insulin plus basal insulin dose therapy on islet β-cell protective effect of.doc

 PAGE \* MERGEFORMAT 14 Promote secretion of insulin plus basal insulin dose therapy on islet β-cell protective effect of Author: Yu-Mei Huang Yuan-lun LIANG Rui Pan Tai-hu Keywords: Type 2 diabetes, insulin In type 2 diabetes (T2DM) patients, the appropriate complement of insulin could protect islet β cells, this view has been recognized, but to achieve β-cell protection best practices for treatment goals are still not reached a consensus. Authors therefore conducted parallel randomized controlled study. In T2DM patients, the application of sulfonylurea or a sulfonylurea plus insulin glargine therapy in the treatment of pre-and post OGTT test, by measuring the islet β-cell damage reflecting the degree of direct or indirect marker level changes, to evaluate the two kinds of treatment methods for the fasting and postprandial β-cell secretory function. A clinical data 1.1 Object and group Study, 20 cases were voluntarily signed the informed consent, and by the moral and ethics committee approval. Previously used alone in patients with glimepiride (Amaryl) in the treatment at least 3 months, the dose (2.6 ± 1.2) mg / d, selected continue to apply after glimepiride treatment 7d, dose (2.6 ± 1.2) mg 1 time / d. And then randomly assigned to continue to glimepiride (Amaryl) in the treatment group and glimepiride (Amaryl) plus bedtime basal insulin (insulin glargine - came when - French Sanofi-Aventis) treatment group. Alone glimepiride group of 10 cases, 7 males and 3 females, age (61 ± 11) years of age, BMI (30.1 ± 2.8) kg/m2, HbA1c (7.0 ± 1.0)%, course of disease (6.5 ± 12.5) years, continue to use Glimepiride 7d, (2.6 ± 1.2) mg 1 time / d; glimepiride plus insulin glargine group of 10 cases, 8 males and 2 females, age (63 ± 8) years of age, BMI (32.0 ± 5.5) kg/m2, HbA1c (6.9 ± 1.2)%, course of disease (5.9 ± 5.3) years, the 8th day came when the Canadian 8U / times, bedtime subcutaneous injection. 1.2 Methods Stud